Preclinical studies of effectiveness and safety of iron oxide nanoparticles based MRI contrast agent for tumor diagnostics

Abstract

agnetic iron oxide nanoparticles (MNP) show great potential as the contrast agent for magnetic resonance imaging (MRI). Purpose. To evaluate the efficiency and safety of the contrast agent based on HSA-coated MNP on the model of the C6 glioma. Materials and methods. Extensive preclinical research of specific activity has been performed. Studies were conducted on the model of the orthotopic C6 glioma. Results. In the preclinical studies, it was demonstrated that HSA-coated magnetic iron oxide nanoparticles (MNP-HSA) accumulate in the tumor and its large vessels. Conclusion. Magnetic resonance imaging with contrast agent allows visualization of the tumor tissue and its vascularization.